ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

ProQR Therapeutics (NASDAQ:PRQR) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02), Zacks reports. ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 55.54%. The company had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $7.05 million.

ProQR Therapeutics Price Performance

NASDAQ PRQR traded up $0.01 on Friday, reaching $2.22. The company had a trading volume of 526,627 shares, compared to its average volume of 600,782. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.21. The firm has a 50-day moving average of $2.40 and a 200-day moving average of $2.11. The firm has a market capitalization of $233.57 million, a PE ratio of -4.72 and a beta of 0.16.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PRQR. Osaic Holdings Inc. grew its stake in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares in the last quarter. Jane Street Group LLC boosted its position in ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 79,720 shares during the last quarter. Bank of America Corp DE grew its stake in ProQR Therapeutics by 25.7% in the second quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 24,347 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in ProQR Therapeutics by 28.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 26,893 shares during the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PRQR shares. Evercore ISI reissued an “outperform” rating on shares of ProQR Therapeutics in a research report on Friday, July 11th. Chardan Capital restated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 15th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.14.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).